Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20
Not Applicable
- Conditions
- Multiple myeloma expressing CD20
- Registration Number
- JPRN-UMIN000000531
- Lead Sponsor
- Zenyaku Kogyo Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who meet any one of the following criteria should be excluded from this study: 1)pregnant or lactating woman 2)patients with a history of receiving a murine, chimeric, humanized and/or human MoAb. 3) patients showing the following clinical laboratory values: peutrophil<1x109/L serum creatinine>Nu x2[Nu:institution normal upper value] ALT,AST,ALP>Nu x3 peripheral blood tumor cell>2x109/L 4) patients who is addicted to alcohol and/or drug, and/or patients with mental disease. 5)patients who have no other active malignancies, myelodysplastic syndrome, myelofibrosis, serious illness, complication or infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method